BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29420827)

  • 1. Effects of lower versus higher phosphate diets on fibroblast growth factor-23 levels in patients with chronic kidney disease: a systematic review and meta-analysis.
    Tsai WC; Wu HY; Peng YS; Hsu SP; Chiu YL; Chen HY; Yang JY; Ko MJ; Pai MF; Tu YK; Hung KY; Chien KL
    Nephrol Dial Transplant; 2018 Nov; 33(11):1977-1983. PubMed ID: 29420827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of different phosphate binders on fibroblast growth factor 23 levels in patients with chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials.
    Zhao SJ; Wang ZX; Chen L; Wang FX; Kong LD
    Ann Palliat Med; 2022 Apr; 11(4):1264-1277. PubMed ID: 34775773
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Short-Term Effects of Very-Low-Phosphate and Low-Phosphate Diets on Fibroblast Growth Factor 23 in Hemodialysis Patients: A Randomized Crossover Trial.
    Tsai WC; Wu HY; Peng YS; Hsu SP; Chiu YL; Yang JY; Chen HY; Pai MF; Lin WY; Hung KY; Chu FY; Tsai SM; Chien KL
    Clin J Am Soc Nephrol; 2019 Oct; 14(10):1475-1483. PubMed ID: 31519550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale and Approaches to Phosphate and Fibroblast Growth Factor 23 Reduction in CKD.
    Isakova T; Ix JH; Sprague SM; Raphael KL; Fried L; Gassman JJ; Raj D; Cheung AK; Kusek JW; Flessner MF; Wolf M; Block GA
    J Am Soc Nephrol; 2015 Oct; 26(10):2328-39. PubMed ID: 25967123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased FGF23 protects against detrimental cardio-renal consequences during elevated blood phosphate in CKD.
    Clinkenbeard EL; Noonan ML; Thomas JC; Ni P; Hum JM; Aref M; Swallow EA; Moe SM; Allen MR; White KE
    JCI Insight; 2019 Feb; 4(4):. PubMed ID: 30830862
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phosphate, fibroblast growth factor 23 and retinopathy in chronic kidney disease: the Chronic Renal Insufficiency Cohort Study.
    Mehta R; Ying GS; Houston S; Isakova T; Nessel L; Ojo A; Go A; Lash J; Kusek J; Grunwald J; Wolf M;
    Nephrol Dial Transplant; 2015 Sep; 30(9):1534-41. PubMed ID: 25910495
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of Nicotinamide and Lanthanum Carbonate on Serum Phosphate and Fibroblast Growth Factor-23 in CKD: The COMBINE Trial.
    Ix JH; Isakova T; Larive B; Raphael KL; Raj DS; Cheung AK; Sprague SM; Fried LF; Gassman JJ; Middleton JP; Flessner MF; Block GA; Wolf M
    J Am Soc Nephrol; 2019 Jun; 30(6):1096-1108. PubMed ID: 31085679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of ferric citrate on serum phosphate and fibroblast growth factor 23 among patients with nondialysis-dependent chronic kidney disease: path analyses.
    Block GA; Pergola PE; Fishbane S; Martins JG; LeWinter RD; Uhlig K; Neylan JF; Chertow GM
    Nephrol Dial Transplant; 2019 Jul; 34(7):1115-1124. PubMed ID: 30380116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on fibroblast growth factor 23 in chronic kidney disease.
    Wolf M
    Kidney Int; 2012 Oct; 82(7):737-47. PubMed ID: 22622492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dietary phosphate restriction and phosphate binders on FGF23 levels in CKD.
    Isakova T; Barchi-Chung A; Enfield G; Smith K; Vargas G; Houston J; Xie H; Wahl P; Schiavenato E; Dosch A; GutiƩrrez OM; Diego J; Lenz O; Contreras G; Mendez A; Weiner RB; Wolf M
    Clin J Am Soc Nephrol; 2013 Jun; 8(6):1009-18. PubMed ID: 23471131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectiveness of fibroblast growth factor 23 lowering modalities in chronic kidney disease: a systematic review and meta-analysis.
    Takkavatakarn K; Wuttiputhanun T; Phannajit J; Praditpornsilpa K; Eiam-Ong S; Susantitaphong P
    Int Urol Nephrol; 2022 Feb; 54(2):309-321. PubMed ID: 33797709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of fractional phosphate excretion on the relation of FGF23 with outcome in CKD patients.
    Bech AP; Bouma-de Krijger A; van Zuilen AD; Bots ML; van den Brand JA; Blankestijn PJ; Wetzels JF; Vervloet MG
    J Nephrol; 2015 Aug; 28(4):477-84. PubMed ID: 25700931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FGF23: a mature renal and cardiovascular risk factor?
    Zoccali C; Yilmaz MI; Mallamaci F
    Blood Purif; 2013; 36(1):52-7. PubMed ID: 23735695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of dietary iron intake and chronic kidney disease on fibroblast growth factor 23 metabolism in wild-type and hepcidin knockout mice.
    Hanudel MR; Chua K; Rappaport M; Gabayan V; Valore E; Goltzman D; Ganz T; Nemeth E; Salusky IB
    Am J Physiol Renal Physiol; 2016 Dec; 311(6):F1369-F1377. PubMed ID: 27733366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of a non-calcium-based phosphate binder on fibroblast growth factor 23 in chronic kidney disease.
    Spatz C; Roe K; Lehman E; Verma N
    Nephron Clin Pract; 2013; 123(1-2):61-6. PubMed ID: 23774446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FGF23 and Phosphate-Cardiovascular Toxins in CKD.
    Vogt I; Haffner D; Leifheit-Nestler M
    Toxins (Basel); 2019 Nov; 11(11):. PubMed ID: 31698866
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Level of phosphate diets effect on fibroblast growth factor-23 levels in chronic kidney disease subjects: A meta-analysis.
    Li Z; Hu M; Guo Y; Zhang L; Peng Y; Abdelrahim MEA; Jiang X
    Int J Clin Pract; 2021 Jul; 75(7):e14195. PubMed ID: 33792113
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Omega-3 Fatty Acid Supplementation on Plasma Fibroblast Growth Factor 23 Levels in Post-Myocardial Infarction Patients with Chronic Kidney Disease: The Alpha Omega Trial.
    de Borst MH; Baia LC; Hoogeveen EK; Giltay EJ; Navis G; Bakker SJL; Geleijnse JM; Kromhout D; Soedamah-Muthu SS
    Nutrients; 2017 Nov; 9(11):. PubMed ID: 29137111
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Simultaneous management of disordered phosphate and iron homeostasis to correct fibroblast growth factor 23 and associated outcomes in chronic kidney disease.
    Courbon G; Martinez-Calle M; David V
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):359-366. PubMed ID: 32452919
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relation between Red Cell Distribution Width and Fibroblast Growth Factor 23 Cleaving in Patients with Chronic Kidney Disease and Heart Failure.
    van Breda F; Emans ME; van der Putten K; Braam B; van Ittersum FJ; Kraaijenhagen RJ; de Borst MH; Vervloet M; Gaillard CA
    PLoS One; 2015; 10(6):e0128994. PubMed ID: 26079688
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.